Gameto Raises $33 Million in Series B Financing to Advance Development and Commercialization of Novel Fertility Treatments
Summary
Following productive discussions with the U.S. Food and Drug Administration, Gameto received tentative approval to proceed to Phase 3 trials, subject to the completion of certain assay and manufacturing requirements. "Gametos novel approach uses cellular engineering to create a pure population of highly potent OSCs from a female clinical-grade human induced pluripotent stem cell (hiPSC) line that recreates the dynamic, bidirectional follicular environment in a dish when co-cultured with immature eggs. "In addition to making treatments much easier and more accessible for women, Gametos advanced IVF/egg-freezing solution addresses a massive societal need as were living longer and looking to start families later in life while facing rising female and male infertility rates. By harnessing cutting-edge breakthroughs in genetic sequencing and cellular engineering tools that didnt exist until recently Gameto is poised to upend traditional IVF treatments to make them more accessible, convenient, and faster for anyone to start a family. Fertilo has received different regulatory classifications in foreign jurisdictions, and after consultation with national regulators, has been cleared for commercialization in Australia and in large markets in Latin America.Gameto is a biotechnology company developing novel treatment solutions for womens health, starting with infertility.